-
Aurinia Pharmaceuticals (AUPH) PT Raised to $35 as H.C. Wainwright Sees LUPKYNIS Approval As a Watershed Event
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $30 at H.C. Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $33 at H.C. Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $32 at H.C. Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $25 at H.C. Wainwright On 8 Year Revenue Stream Extension
-
Aurinia Pharmaceuticals (AUPH) 4Q Catalyst Coming Into View - HCWainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $15 at H.C. Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $12 at H.C. Wainwright; 'R&D Day Showcases New Indications, Expanded Opportunity'
-
Aurinia Pharmaceuticals (AUPH): Cutting PT On Dilution - HC Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Raised to $12 at H.C. Wainwright Following Recent Positive Data
-
Aurinia Pharmaceuticals (AUPH): First Take On CEO Transition - HC Wainwright
-
Aurinia Pharmaceuticals (AUPH) PT Trimmed to $8 at H.C. Wainwright on Dilution; 'Buy' Maintained
-
Aurinia Pharmaceuticals (AUPH): EOP2 Meeting Results Were Better Than Could Have Been Hoped For - HC Wainwright
-
Aurinia Pharmaceuticals (AUPH): Reiterating $10 PT After The Recent 33% Move - HC Wainwright

